Health

News Hour: IOM Ghana’s Global Health Security Agenda (GHSA) programme is helping Kotoka International Airport (KIA) to develop a Public Health Emergency Contingency Plan (PHECP) tailored for the operations and capacity of the airport. The formulation...

Women Deliver, a global advocacy organization, awarded seed grants of US$5,000 each to 10 Young Leaders to support digital storytelling projects raising awareness and supporting positive communications in communities about access to contraception and young people’s...

News Hour: Missouri Cancer Associates, the premier cancer treatment center in mid-Missouri and an affiliate of The US Oncology Network, has added another physician to the practice to meet growing demand for its services. Liana Makarian,...

News Hour: Biogen Inc. (NASDAQ: BIIB)  reported second quarter 2016 financial results, including: Total revenues of $2.9 billion, a 12% increase versus the same period in the prior year. Growth was driven by increases in worldwide...

News Hour: The Marketing Authorization Application (MAA) for SB5, an adalimumab biosimilar candidate referencing Humira®, has been accepted for review by the European Medicines Agency (EMA). The MAA for SB5 is the third anti-TNF biosimilar candidate...

News Hour: The European Commission (EC) has granted marketing authorization for ZINBRYTA™ (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced last month....

News Hour: Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS)  announced that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint pre-specified for the interim analysis of ENDEAR, the Phase 3 trial evaluating nusinersen...

News Hour: Merck (NYSE:MRK), known as MSD outside of the United States and Canada,  announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for MK-1293, an investigational...

News Hour: Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, at a fixed...

News Hour: GSK (LSE/NYSE: GSK)  announced an agreement with Verily Life Sciences LLC (formerly Google Life Sciences), an Alphabet company, to form Galvani Bioelectronics to enable the research, development and commercialisation of bioelectronic medicines. GSK will...